The effect of conjugated estrogens/bazedoxifene therapy on body weight of postmenopausal women: pooled analysis of five randomized, placebo-controlled trials.

Abstract

OBJECTIVE:

This post hoc analysis compared body weight, body mass index (BMI), and BMI category changes in postmenopausal women treated with conjugated estrogens/bazedoxifene (CE/BZA) versus placebo in the Selective Estrogens, Menopause, and Response to Therapy (SMART) trials.

METHODS:

Data were pooled from five randomized, double-blind, placebo- and active-controlled studies in postmenopausal women aged 40 to 75 years with a uterus given CE 0.45 mg/BZA 20 mg (n = 1,607), CE 0.625 mg/BZA 20 mg (n = 1,598), or placebo (n = 1,256) for at least 12 weeks and up to 2 years. Changes from baseline in body weight, BMI (kg/m(2)), and World Health Organization BMI category (underweight <18.5; normal 18.5 to <25; overweight 25 to <30; obese ≥30) during treatment were evaluated.

RESULTS:

Mean body weight increased less than 0.9 kg and mean BMI increased less than 0.4 kg/m(2) in all treatment groups at all time points. There were no statistically significant between-group differences, except for significantly greater increases in weight (P = 0.015) and BMI (P = 0.014) with placebo versus CE 0.625 mg/BZA 20 mg at month 12. Approximately, 10% of women in the CE/BZA groups and 11% in the placebo group had increases in body weight greater than 7% of baseline. The majority of BMI changes were within ±7%, and there were no statistically significant between-group differences in BMI category distributions during treatment.

CONCLUSIONS:

Significant increases in body weight or BMI were not observed in postmenopausal women receiving CE 0.45 mg/BZA 20 mg or CE 0.625 mg/BZA 20 mg for up to 2 years in the Selective Estrogens, Menopause, and Response to Therapy trials.

• Authors: Denise Black, Michael Messig, Ching-Ray Yu, Annlouise R Assaf, Barry S Komm, Sebastian Mirkin, Matthieu Boucher
• Journal: Menopause (New York, N.Y.) (Menopause) Vol. 23 Issue 4 Pg. 376-82 (Apr 2016) ISSN: 1530-0374 [Electronic] United States
• PMID: 26694733 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Estrogens, Conjugated (USP)
• Indoles
• Placebos
• Selective Estrogen Receptor Modulators
• bazedoxifene

Topics

• Adult
• Aged
• Body Mass Index
• Body Weight (drug effects)
• Double-Blind Method
• Estrogens, Conjugated (USP) (adverse effects, therapeutic use)
• Female
• Hot Flashes (drug therapy)
• Humans
• Indoles (adverse effects, therapeutic use)
• Middle Aged
• Placebos
• Postmenopause
• Selective Estrogen Receptor Modulators